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Toxoplasma gondii is an intracellular parasite of all mammals and birds, responsible for
toxoplasmosis. In healthy individuals T. gondii infections mostly remain asymptomatic,
however this parasite causes severe morbidity and mortality in immunocompromised
patients and congenital toxoplasmosis in pregnant women. The consumption of raw or
undercooked pork is considered as an important risk factor to develop toxoplasmosis
in humans. Since effective therapeutic interventions to treat toxoplasmosis are scarce,
vaccination of meat producing animals may prevent T. gondii transmission to humans.
Here, we evaluated the elicited immune responses and the efficacy of a potential vaccine
candidate, generated by size fractionation of T. gondii lysate proteins, to reduce the
parasite burden in tissues from experimentally T. gondii infected pigs as compared to
vaccination with total lysate antigens (TLA). Our results show that both the vaccine
candidate and the TLA immunization elicited strong serum IgG responses and elevated
percentages of CD4+CD8+IFNγ+ T cells in T. gondii infected pigs. However, the TLA
vaccine induced the strongest immune response and reduced the parasite DNA load
below the detection limit in brain and skeletal muscle tissue in most animals. These
findings might inform the development of novel vaccines to prevent T. gondii infections
in livestock species and humans.
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INTRODUCTION
Toxoplasma gondii is a ubiquitous obligate intracellular apicomplexan parasite that may cause
toxoplasmosis in endothermic animals including humans. The acute stage of infection is
predominantly transient and transforms into a latent and chronic phase in which the parasite
localizes within tissue cysts, mainly in the central nervous system (1). Although T. gondii infection
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is mostly asymptomatic in immunocompetent individuals, it
might cause occasional illness, such as- muscle aches, tender
lymph nodes, and eye problems (2). T. gondii develops
tissue cysts in brain tissue, which has been associated with
a vast array of psychiatric and behavioral disorders, such as
schizophrenia and obsessive–compulsive disorder (3). Indeed,
chronic T. gondii infections alter the morphology and function
of neurons, dysregulating the release of neurotransmitters (3, 4).
In addition, during pregnancy T. gondii infection can result in
congenital toxoplasmosis, leading to abortion, stillbirth or birth
defects (5).
Infection in humans generally occurs through the
consumption of food or drinks contaminated with cat shed
oocysts that sporulate in the environment, or through the
consumption of raw or undercooked meat that contains tissue
cysts (4–6). Other routes of infection are congenital transmission
and organ transplantation (7). Raw and undercooked meat
accounts for 30–63% of T. gondii infections in humans (8, 9)
and according to the prevalence estimates of T. gondii in meat
producing animals/meats, pork consumption was estimated to
account for 12–15% of T. gondii infections in humans (10, 11).
As such, preventing or treating T. gondii infections in pigs might
help to reduce infection of humans.
Although toxoplasmosis is of great medical and veterinary
importance, treatment of this disease is difficult. There are
a number of drugs on the market, however their efficacy is
variable when the treatment is started in an advanced stage
of the infection and reactivation of the parasites may occur
at any time (7, 12). As such, preventive interventions, like
vaccination, that decrease the risk of contact with T. gondii
are of utmost importance. Presently, only one commercial
vaccine, Toxovax, that is based on the live attenuated T. gondii
strain S48, has been licensed for sheep in some countries
(13). However, this vaccine is expensive, causes adverse effects,
has a short shelf-life and may revert to virulence (14). In
addition, there is a knowledge gap whether this vaccine
offers protection against T. gondii infection in other livestock
species. Vaccination of pigs with T. gondii antigens incorporated
in ISCOMs (immunostimulating complexes) elicited humoral
immune responses, however it was not assessed if this vaccine
affects the number of tissue cysts after challenge with T. gondii
(15). Recently, it has been demonstrated that vaccination of
pigs with T. gondii S48 strain might reduce the parasite load
in skeletal muscles (16). For safety reasons and the issues
described above, numerous research efforts have focused on the
development of new vaccination strategies against toxoplasmosis,
such as the development of DNA vaccines and subunit vaccines
Abbreviations: Cp, Crossing point (also known as Ct or Cq); ELISA,
Enzyme-Linked ImmunoSorbent Assay; IFA, Indirect Immunofluorescence
Assay; MAT, Modified Agglutination Test; MC-qPCR, Magnetic Capture-
Quantitative Polymerase Chain Reaction; PBS, Phosphate-buffered saline; ng/ml,
Nanogram/milliliter; TLA, Total Lysate Antigen; FACS, Fluorescence-activated cell
sorting; IFN-γ, Interferon gamma; PBMCs, Peripheral blood mononuclear cells;
LOD, Limit of detection; SD, Standard deviation; CD, Cluster of differentiation;
NK cells, Natural killer cells; IL, Interleukin; APCs, Antigen presenting cells;
CTLs, Cytotoxic T lymphocytes; Th cells, T helper cells; CCE, Continuous elution
electrophoresis; kDa, Kilodalton; MW, Molecular Weight.
(17). These novel vaccine candidates need to elicit CD8+
cytotoxic T cell (CTL) responses, as the protection against
T. gondii infection is mainly attributed to cellular immunity
(14). However, there are two important obstacles hindering to
meet this requirement. First, the immunogenicity of vaccine
candidates should be enhanced. Purified T. gondii antigens
exhibit a lower immunogenicity in contrast to live attenuated
T. gondii vaccines as the latter are self-adjuvanting, mediated in
part by cell wall and internal components. Therefore, adjuvants
are often used in vaccine candidates to elicit better responses.
For instance, in pigs a saponin-based adjuvant might be a
good choice as it can promote systemic antibody responses,
CTL responses and mucosal immune responses (18). A second
hurdle comprises the limited information about potential vaccine
antigens and their immunogenicity in pigs. To our knowledge,
T. gondii elicits complex cellular immune responses that could
differ considerably between host species and/or T. gondii strains.
For example, during early T. gondii infection in sheep, the
parasite triggers T cell independent IFNγ and IL-12 secretion,
which are most likely crucial for resistance against the parasite.
However, antigen-specific T cell dependent responses dominate
around 8 days post infection (19). Apart from this, species-
specific antibody responses were observed. In sheep infected
with the T. gondii Prugniaud strain, antibodies appear against
all tested T. gondii antigens (TLA, rGRA1, rGRA7, rEC2, or
rMIC3), whereas in pigs only weak rGRA7-specific and even
weaker TLA-specific antibody responses could be demonstrated
when infected with the T. gondii IPB-Gangji strain (20, 21).
T. gondii strains also differ considerably in their ability to
trigger T cell responses. For instance, pigs inoculated with
the T. gondii IPB-LR strain showed a significant increase in
IFNγ+ T cell subsets (e.g., CD4+CD8α−, CD4+CD8αdim, and
CD4−CD8αbright), while upon inoculation with the T. gondii
IPB-Gangji strain the increase in the CD4−CD8αbright T cells was
clearly less pronounced (21). Nevertheless, a high dose of the
IPB-Gangji strain elicited an immune response that resulted in
a reduced parasite load, while a high dose of the IPB-LR strain
did not affect the T. gondii distribution or load (21). In rats
(intermediate host) and cats (definitive host) on the other hand
a high dose of tachyzoites or bradyzoites resulted in a higher
number of tissue cysts and a decreased survival rate of animals
(22, 23). These discrepancies obviously complicate studies that
aim to elucidate the potential of vaccine candidates to protect the
host from T. gondii infections.
Here, we chose two different vaccine candidates in an
effort to identify antigens which might provide protection
against T. gondii infection in pigs upon their inclusion in
vaccines. We opted for T. gondii lysate antigens (TLA) as
vaccine candidate as TLA covers a wide range of potential
protective antigens. To identify these potential protective
antigens, proteins within TLA were size fractionated as
this allows their unbiased separation. Upon evaluating the
antigenicity of each size fraction, two selected fractions were
combined as a second vaccine candidate. The humoral and
cellular immune responses elicited by these two vaccine
candidates as well as the parasite DNA load in selected tissues
were evaluated.
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MATERIALS AND METHODS
T. gondii Strain
The T. gondii IPB-LR strain was used for experimental infections
in pigs. This less pathogenic strain, originally isolated from
pigs, belongs to genotype II, which is commonly present in the
European pig population (21, 24, 25). There were two reasons
to use this strain. Inoculation with the IPB-LR strain resulted
in a more consistent infection and the parasite load in tissues
could be reduced by a subsequent infection with the IPB-
Gangji strain (21). The IPB-LR strain was maintained at the
National Reference Laboratory for Toxoplasmosis (Sciensano,
Brussels, Belgium) by passage in Swiss female mice. Tissue cysts
were harvested from brain tissue, counted by phase-contrast
microscopy and suspended in sterile phosphate buffered saline
(PBS) at a concentration of 700 tissue cysts/ml (21). In addition,
the T. gondii RH strain was used for the production of antigens.
Vaccine Antigen Preparation
T. gondii lysate antigen (TLA) was prepared from tachyzoites
of the RH-strain as previously described (17) and stored at
−20◦C until further use. To evaluate the protein content of
the lysate, the bicinchoninic acid (BCA) reaction (Thermo
Scientific Pierce BCA protein Assay Kit, Erembodegem, Belgium)
was used. To separate TLA proteins according to their size
a continuous-elution electrophoresis technique was used. TLA
proteins (10mg) were diluted (1:1) in loading buffer (0.04%
w/v Bromophenol Blue, 0.04% w/v Xylene Cyanole FF, 6.66 %
w/v Sucrose, 5% v/v ß mercaptoethanol) and denatured at 95◦C
for 5min. Subsequently, the material was loaded on a 7.5%
SDS-PAGE cylindrical gel (length 8 cm × diameter 3.7 cm) for
continuous elution electrophoresis (PrepCell, Bio-Rad). During
a run, TLA proteins migrated through the cylindrical gel matrix
with running buffer (0.12mM Tris-base, 0.96M glycine, 0.5%
SDS) as ring-shaped bands according to their molecular weight.
The fractions were harvested in collection tubes (3.5ml/tube) and
aliquots (30 µl) were screened for the presence of TLA antigens
by 7.5% SDS-PAGE and Western blotting. Upon blocking in
PBS + 5% milk powder + 0.3% tween R©80, transferred proteins
were detected with T. gondii-specific pig serum (in house;
1/100 dilution) and goat anti-pig IgG-HRP (Bethyl, 1/1,000
dilution). Finally, western blot substrate (Pierce R©ECL, Thermo
Fisher Scientific) was applied as luminol enhancer and visualized
using a ChemiDocMP Imager (BioRad, USA). According to
the western blot results (Supplement Figure 1), we divided the
TLA protein fractions in six pools according to their molecular
weight: Pool 1 (20–40 kDa), Pool 2(40–55 kDa), Pool 3 (55–
65 kDa), Pool 4 (65–80 kDa), Pool 5 (80–100 kDa), and Pool
6 (100–120 kDa). We further tested the immunogenicity of
these pools in an antigen recall assay as described (21), which
showed that pool 1 and 3 displayed the highest immunogenicity
(Supplement Figure 2). Based on these results, we decided to
combine pool 1 (20–40 kDa) and 3 (55–65 kDa) for vaccination
(vaccine 1). At the same time, complete TLA was prepared as
vaccine 2. In addition, both vaccines were concentrated and
dialyzed to remove SDS with Amicon R© filter units (cut-off =
10 kDa). Finally, both vaccine candidates were dissolved in
PBS and sterilized by filtration (0.22µm, low protein binding
filters, Millex-GV). Protein concentrations were determined by
BCA assay.
Experimental Setup
Nineteen 3-week-old piglets (Belgian Landrace × Large White)
were confirmed to be T. gondii seronegative by the modified
agglutination test (ToxoScreen DA, Biomérieux, Capronne,
France) and an immunofluorescence test (Toxo-Spot IF,
Biomérieux) as described (20). The piglets were randomly
divided into four groups: control (n = 2), adjuvant (n = 2),
vaccine 1 (n = 5), and vaccine 2 (n = 5). Figure 1 shows the
timeline of the vaccination experiment. At day zero (D0) the
piglets received an intramuscular (IM) immunization in the neck
with vaccine 1 (500 µg antigens, 300 µg QuilA in 1.5ml PBS),
vaccine 2 (500µg antigens, 300µgQuilA in 1.5ml PBS), adjuvant
(300µg QuilA) or were not immunized (control). At 54 days post
immunization piglets were orally inoculated with 3,500 T. gondii
tissue cysts and 61 days post primary immunization (7 days
post inoculation) a booster vaccination was given. We followed
this immunization scheme to obtain a booster response that
could optimally interfere with the infection since our previous
study using a heterologous challenge infection suggested that
the early immune response was able to clear the parasite from
tissues (21). Blood was sampled at the indicated time points in
Figure 1 to evaluate serum antibody responses by ELISA and
the function of peripheral immune cells in an in vitro recall
assay. At the end of the study, pigs were euthanized by injecting
sodium pentobarbital (20%, 0.125 ml/kg body weight, IV) and
following exsanguination, tissue samples were collected to assess
the parasite load.
T. gondii Antigen-Specific ELISA
Blood samples were collected in vacuum tubes (Vacutest KIMA,
Italy) from the vena jugularis according to the scheme shown
in Figure 1. The blood samples were allowed to clot at room
temperature for 30min. Serum samples were collected upon
centrifugation at 15,000 g for 10min, aliquoted and stored at
−20◦C until further use. TLA, pool 1 and pool 3 antigen-
specific serum IgG antibody responses were evaluated by ELISA
as described (20). Briefly, 96-well microtiter plates were coated
separately with TLA (5µg/ml, Microbix Biosystems, Canada),
pool 1 (5µg/ml size fractionated antigens), and pool 3 (5µg/ml
size fractionated antigens), serial diluted serum samples were
added and detected with HRP-conjugated anti-porcine IgG
(Bethyl Laboratories Inc., Montgomery, Texas, USA) and ABTS
[2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)] as a
substrate (18). On each plate previously collected sera from
positive and negative control animals, as established by IgM and
IgG immunofluorescence assay (IFA), were included as a first
line control. The absorbance at 405 nm was measured with a
microplate reader (TECAN Spectra Fluor, Tecan Group Ltd.,
Männedorf, Switzerland) and the obtained data were analyzed
in GraphPad Prism 6 software to discriminate IgG antibody
responses between groups. Serum samples from infected animals
were considered positive when exceeding the cut-off value (=
mean OD405 negative controls + 3x the standard deviation).
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FIGURE 1 | Scheme of the vaccination and challenge experiment. Experiment day indicated as numbers (0–140). TLA-ELISA: T. gondii lysate antigen-specific
enzyme-linked immunosorbent assay. PBMCs, peripheral blood mononuclear cells. MCqPCR, magnetic capture real time quantitative polymerase chain reaction.
Antibody titers were calculated as the inverse of that dilution with
a signal above the cut-off value.
In vitro Recall Assay
Blood was sampled on heparin and PBMCs were isolated by
Lymphoprep R© gradient density centrifugation as described
(21). PBMCs were seeded at 1 × 106 cells/well in leukocyte
medium (RPMI-1640, Thermo scientific, Merelbeke,
Belgium) supplemented with fetal calf serum (10%, Greiner
Bio-One, Merelbeke Belgium), non-essential amino acids
(100mM; Gibco), sodium pyruvate (100µg/ml), L-glutamine
(292µg/ml; Gibco), penicillin (100 IU/ml; Gibco), streptomycin
(100µg/ml; Gibco), and kanamycin (100µg/ml; Gibco) and
were incubated with 20µg/ml pool 1, pool 3, TLA or medium
for 72 h. After incubation, 1 µl GolgiPlug (BD Biosciences)
was added to each well for 6 h. Then, the cells were fixed and
permeabilized using the Cytofix/Cytoperm kit (BD Biosciences)
and stained using monoclonal antibodies (mAb) against CD3
(IgG1, clone PPT3), CD4 (IgG2b, clone 72–14-4), and CD8
(IgG2a, clone 11/295/33) and the secondary antibodies goat anti-
mouse IgG1-PerCP-Cy5.5 (Santa Cruz Biotechnology, Dallas,
Texas, USA), goat anti-mouse IgG2b-FITC (Southernbiotech,
Birmingham, Alabama, USA) and goat anti-mouse IgG2a-Alexa
Fluor 647 (ThermoFisher Scientific). Finally, for intracellular
IFNγ staining, phycoerythrin (PE)-conjugated mAb against
porcine IFNγ (mouse IgG1, BD Biosciences) was added. A
minimum of 25,000 events were recorded within the CD3+ gate
(Supplement Figure 4) and the percentage of IFNγ+ cells in the
different lymphocyte subsets was determined using a CytoFLEX
and Flow Cytometer software (both from Beckman Coulter).
Finally, the percentage of IFNγ+ T cells were recalculated by
subtracting the % IFNγ+ cells in unstimulated conditions from
those with stimulation.
IFNγ ELISA
IFNγ secretion was determined in the supernatant (1/10 dilution)
of PBMCs cultured in medium or stimulated with antigens as
described above with a sandwich ELISA using the swine-specific
IFNγ antibody pair kit (ThermoFisher). The limit of detection of
this ELISA was determined at 12.3 pg/ml.
Magnetic Capture qPCR
The selection of tissue samples to assess parasite load in animals
was based on our previous T. gondii IPB LR and/or Gangji
strain infection study, in which we demonstrated that the tissues
with the highest parasite load were detected in brain and heart
followed by skeletal muscle intercostales, longissimus dorsi, psoas
major, diaphragm, and gastrocnemius via Magnetic Capture
qPCR (21).
The tissue samples from brain, heart and the skeletal muscles
gastrocnemius and longissimus dorsi were collected from all pigs.
The parasite load was determined by an ISO 17025 validated
magnetic capture qPCR as previously described (26), in which
the magnetic isolation of T. gondii-specific DNA from large tissue
samples (>100 g) was combined with the sensitivity of qPCR. In
addition, the developed MCqPCR has a sensitivity of 99% and a
better limit of detection (26) than a previous MCqPCR (27).
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All the samples with an exponential amplification curve
crossing the threshold (Cq) were considered positive for T.
gondii, while samples with no amplification curve for the T.
gondii target, but amplification of the NCIAC (Not Competitive
Internal Amplification Control) were considered negative. The
detection limit of this method is 65.4 parasites per 100 g of
tissue sample. For each round of samples, a positive control
with a known number of parasites (calibrator) was included
to correct for possible deviations due to manipulation errors.
The number of parasites (n◦ p) was calculated according to the
following formula:
log10
(
n◦p
)
=
Cqvalue − 44.75
−3.0788
(1)
The formula resulted from a standard curve established with
known concentrations of parasites ranging from 100 to 105
spiked in 100 g of muscle tissue samples or in 50 g of brain tissue
(28). Log10(n
◦ P) represents the log10-transformed parasitic
load, while the Cqvalue represents the point on the exponential
amplification curve crossing the threshold.
Data Analysis
The antibody responses, IFNγ response and T. gondii parasite
load in tissue samples of the different groups are presented as
mean ± SD. Individual group kinetics were analyzed with a
repeated measures analysis of variance by the Friedman test and
data between groups were analyzed by the Kruskal-Wallis test
with a post-hoc analysis via Dunn’s test. Multiple comparisons
and computation of CIs along with significances were applied
to discriminate between vaccinated and control groups. In all
analyses p< 0.05 was considered statistically significant.
RESULTS
T. gondii Vaccine Candidates Differ in Their
Ability to Elicit Serum Antibody Responses
Previously, we obtained a strong indication that the early
immune response following infection with the T. gondii IPB
Gangji strain could clear the IPB LR strain in a heterologous
challenge infection (21). Since we aimed to maximize the
immune response of our experimental vaccines, we decided,
based on this previous study, to orally challenge the vaccinated
pigs with 3,500 tissue cysts of the T. gondii IPB LR strain seven
days prior to the booster vaccination.
As potential vaccines we selected TLA (vaccine 2), this T.
gondii lysate contains a lot of potential protective antigens. In
an effort to enrich these potential protective antigens, the TLA
proteins were size fractionated and their reactivity with T. gondii
specific pig serum was confirmed (Supplement Figure 1). In
addition, we observed that two pools, pool 1 and 3, elicited
a robust T cell activation in an in vitro antigen recall assay
(Supplement Figure 2). Based on these findings, pool 1 and pool
3 were selected to be included in vaccine 1.We then compared the
ability of the two vaccine candidates to trigger immune responses
in pigs.
As shown in Figure 2, upon intramuscular administration
only vaccine 2 induced strong TLA-specific serum IgG responses
(P = 0.02) at D28 compared to vaccine 1 and control groups,
respectively. In addition, TLA-specific IgG serum responses were
significantly higher in vaccine 2 group at D68 (P = 0.03)
and at D82 (P = 0.02) upon challenge infection compared to
the adjuvant group. Upon challenge infection with T. gondii
tissue cysts, TLA-specific serum IgG responses were significantly
increased in vaccine 2 group at D68 (P = 0.008) and at D96
(P = 0.019) and in vaccine 1 group at D68 (P = 0.008)
compared to pre-challenge IgG levels and persisted throughout
the study period, which corresponds with previous observations
(29). Apart from this, the kinetics of the pool 1 and pool 3-
specific serum IgG responses in all groups matched the TLA
specific serum IgG response. Interestingly, in vaccine 1 group, the
post-vaccination and pre-challenge serum IgG responses kinetics
were clearly detectable, however this response was not detectable
against TLA (Supplement Figure 3 and Figure 2).
Vaccine Candidate 2 Induces a Different
IFNγ Secretion Profile Upon Challenge
Infection
In addition to the TLA-specific IgG responses, we also assessed
the ability of the vaccine candidates to induce cellular immune
responses. After challenge infection, PBMCs were isolated and
stimulated in vitro with medium, TLA, pool 1 or pool 3 antigens
and the IFNγ concentration in the supernatant was evaluated.
In medium stimulated PBMCs the IFNγ level was below the
limit of detection. In contrast, different antigens triggered IFNγ
secretion by PBMCs in all groups (Figure 3). Interestingly, the
IFNγ secretion profile in the vaccine 1 and two control groups
(i.e., control and adjuvant groups) showed a bimodal response
with a first peak of IFNγ secretion at D61 (7 days post infection)
followed by a second peak at D96 (42 days post infection).
We observed such a bimodal response in sheep following T.
gondii infection, suggesting that the effect of vaccine 1 on the
IFNγ response was minimal, which is supported by the similar
response in the control and adjuvant only groups (19, 20). In the
vaccine 1 group, TLA and pool 1 antigens triggered a significant
IFNγ secretion (P = 0.037 and P = 0.044, respectively) at D61,
while at D96 this was only observed for pool 1 antigen (P =
0.006). In contrast, the IFNγ secretion kinetics were completely
different in the vaccine 2 group. The IFNγ secretion steadily
increased from D54 until reaching a maximum at D82 in TLA-
stimulated cells (P = 0.013) and at D96 upon stimulation with
pool 1 (P= 0.023) antigens (Figure 3).
These findings accentuate that vaccine 2 induced IFNγ
secretion by T. gondii-specific immune cells which maintained
their robust IFNγ secretion during infection as compared to the
control and vaccine 1 groups. In an effort to identify the source
of this IFNγ, antigen-stimulated IFNγ producing PBMCs were
phenotyped via FACS analysis.
Different T Cell Subsets Produce IFNγ
Upon Challenge Infection of the Vaccine
Groups
Upon stimulation of PBMCs isolated from challenge infected
piglets, the percentage of IFNγ+ cells in the different T cell
subsets and NK cells was assessed (Figure 4). In addition
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FIGURE 2 | Kinetics of T. gondii specific serum IgG antibody titers upon vaccination and challenge infection. ⊕1 = primary vaccination, ⊕2 = booster vaccination, ⊗
= oral inoculation with T. gondii IPB LR strain tissue cysts. TLA, T. gondii lysate antigens; D, experiment day. The data are presented as the mean ± SD for each
group. *P < 0.05; **P < 0.01. Symbols represent different animals.
to the conventional T cell subsets, pigs also have a large,
unconventional CD4+CD8+ peripheral T cell population (30),
which have been reported to differentiate from CD4+CD8−
cells upon antigen encounter (31). Indeed, this CD4+CD8+ T
cell population exhibit properties of mature antigen-experienced
memory/effector T cells, is characterized by the expression of
IFNγ and plays a role in protection against viral infection (32, 33).
Throughout the study period, significant IFNγ+ T cell
responses were detected in the CD4+CD8+ T cell subset
(Figure 4A), but not in the CD4−CD8+ CTLs, CD4+CD8− Th
cells, CD4−CD8− T cells or CD3−CD8+ IFNγ+ NK cells upon
re-stimulation (Supplement Figures 5, 6A–C and Figure 4B).
Upon stimulation with TLA, the percentage of
CD4+CD8+IFNγ+ T cells significantly increased in the
vaccine 1 group at D68 (P = 0.02) compared to D54.
After a decline at D82, a second peak was observed in the
vaccine 1 group at D96 which is also significant (P = 0.04)
compared to D54 (Figure 4A). On the other hand, in the
vaccine 2 group, upon stimulation with TLA the percentage
of CD4+CD8+IFNγ+ T cells slowly increased from D68 and
reached its maximum at D96 (Figure 4A). A similar profile was
observed upon stimulation with pool 1 and pool 3 antigens,
although for the latter the first peak of IFNγ+ T cells at D68 was
less prominent.
Collectively, these data show that the CD4+CD8+ T cells
are the main IFNγ producers upon challenge infection of
immunized pigs.
Vaccine 2-Induced Immune Responses
Prevented Dissemination of the Parasite to
Brain Tissue in Infected Animals as
Assessed by the Quantification of T. gondii
DNA Load
In order to assess the effect of the vaccination on the ability
of the animals to prevent dissemination of T. gondii parasites
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FIGURE 3 | Kinetics of IFNγ secretion by PBMCs upon challenge infection. Pigs in all groups were inoculated with the T. gondii IPB LR strain at D54. ⊗ = Oral
inoculation with T. gondii IPB LR strain tissue cysts. ⊕2 = Booster vaccination. The data are presented as the mean ±SD. * = TLA vs. medium, x = pool 1 vs.
medium, * or x P < 0.05; xx P < 0.01.
into the host tissues, representative tissue samples, such as
brain, heart, m. longissimus dorsi, and m. gastrocnemius, were
tested by magnetic capture qPCR (MC-qPCR) (26). According
to the MCqPCR results, the control group displayed the highest
parasite load in brain followed by heart, m. gastrocnemius and
m. L. dorsi (Table 1), which corroborates our previous results
(26). Remarkably, in the QuilA adjuvanted control group no
parasite DNA was detected in the m. L. dorsi (Figure 5). In the
vaccine 1 group, the parasite was not detected in brain tissue
of 2/5 pigs, heart of 2/5 pigs, m. L. dorsi of 3/5 pigs, and m.
gastrocnemius of 4/5 pigs. On the other hand, in vaccine 2
group, brain tissues of 5/5 pigs, heart of 2/5 pigs, m. L. dorsi
of 4/5 pigs, and m. gastrocnemius of 4/5 pigs were parasite
DNA negative.
DISCUSSION
The objective of this study was to evaluate the ability of T.
gondii lysate fractions as vaccine candidates to elicit appropriate
immune responses, which could protect pigs from T. gondii
infection. To design a vaccine candidate, two issues were
considered: the choice of antigen and adjuvant. As protection
against T. gondii infection requires a potent cellular immune
response, we adjuvanted the vaccine candidates with QuilA. The
latter elicits robust antibody and cellular immune responses to
a broad range of viral, bacterial, parasitic and tumor antigens
(34, 35). Second, we wanted to include T. gondii antigens
in the vaccine candidate that were able to trigger antibody
and cellular immune responses. For this, T. gondii lysate
proteins were size fractionated and pooled according to their
molecular weight. Based on their immunogenicity and their
ability to elicit IFNγ secretion in an in vitro antigen recall
assay, pool 1 and 3 were combined and used as vaccine
candidate 1. For comparison, complete TLA was used as
vaccine 2.
Despite our selection procedure, only vaccine 2 elicited TLA-
specific serum IgG responses upon intramuscular administration
of a single dose (Figure 2), whereas both vaccines induced
a pool 1- and a lower pool 3-specific serum IgG response
(Supplement Figure 3). This might be explained by the fact
that pool 1 and 3 antigens in vaccine 1 are denatured during
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FIGURE 4 | Kinetics of IFNγ+ T cell subsets in the control and vaccine groups upon challenge infection. (A,B) The percentage of CD4+CD8+ IFNγ+ T cells and
CD3−CD8+ IFNγ+NK cells in TLA, Pool 1 and Pool 3 re-stimulated cells, respectively. The percentage of IFNγ+ T lymphocyte subsets is obtained by subtracting the
%IFNγ+ cells following mock stimulation. ⊗ = Challenge infection with T. gondii IPB LR strain. The data are presented as the mean ± SD. *1 = vaccine 1. *1 P < 0.05.
processing. However, that both pools form only a fraction of
antigens in TLA might also have contributed to the absence
of TLA-specific IgG response after a single dose of vaccine 1.
Nevertheless, vaccine 1 probably still primed the immune system
as the antibody responses upon challenge infection and booster
vaccination were higher as compared to those of the control
groups. Likewise, in vaccine 2 group the post-challenge IgG
titers were significantly higher compared to the control group.
These high T. gondii specific IgG titers upon challenge infection
in all groups, which persisted till the end of the study, are in
line with previous findings, which demonstrated that irrespective
of the T. gondii strain and age of the pigs, parasite-specific
IgG appeared day 7–14 post infection and persisted throughout
life (29).
Although the role of antibodies in protection against T. gondii
is largely unknown, cellular immune responses, andmore specific
IFNγ production, are strongly correlated with resistance against
T. gondii infection (36). In our previous study, we showed IFNγ
production by CD4+ Th cells, CD8+ CTLs and CD4+CD8+
memory T cells of T. gondii-infected piglets in an in vitro
antigen recall assay (21). Here, we showed that upon infection
of the control and vaccine 1 group, CD4+CD8+ T cells secreted
IFNγ upon TLA stimulation in a bimodal response, while in
the vaccine 2 group this IFNγ production by CD4+CD8+ T
cells gradually increased until D96 of the study. These results
indicate that vaccine 2 might have induced T. gondii-specific
IFNγ+ T cells which upon challenge and booster vaccination
of the pigs differentiated into effector memory T cells (37). In
contrast, the bimodal IFNγ response in the control and vaccine
1 group might be explained by an interplay between the life
cycle of the parasite and the induced immune responses. Upon
oral ingestion, tissue cysts release bradyzoites in the intestine,
which transform to tachyzoites. The latter invade and replicate
the surrounding tissues, from which they eventually disseminate
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TABLE 1 | MCqPCR results obtained from different tissues of experimentally infected pigs (100 g muscle tissues or 50 g brain tissue).
Group Brain Heart L. dorsi Gastrocnemius
Control Cp 32.42 29.05 37.13 29.25
P-load 2022.26 25143.13 59.71 21650.05
Cp 29.04 35.46 35.18 33.97
P-load 25331.88 208.18 256.68 634.45
No. of positive pigs/total no. of pigs 2/2 2/2 2/2 2/2
Adjuvant Cp 33.83 31.79 - 34.27
P-load 704.48 3239.38 0 506.94
Cp 31.41 32.43 - 30.56
P-load 4304.15 2007.19 0 8127.72
No. of positive pigs/total no. of pigs 2/2 2/2 0/2 2/2
Vaccine 1 Cp 31.27 33.15 40.03 32.37
P-load 4779.24 1171.47 6.82 2099.31
Cp 34.22 33.60 37.49 -
P-load 526.25 836.70 45.61 0
Cp - 36.59 - -
P-load 0 89.41 0 0
Cp 40.07 - - -
P-load 6.62 0 0 0
Cp - - - -
P-load 0 0 0 0
No. of positive pigs/total no. of pigs 3/5 3/5 2/5 1/5
Vaccine 2 Cp - - - -
P-load 0 0 0 0
Cp - 32.25 35.90 -
P-load 0 2296.43 149.81 0
Cp - 32.83 - 32.56
P-load 0 1488.22 0 1821.23
Cp - - - -
P-load 0 0 0 0
Cp - 36.14 - -
P-load 0 125.19 0 0
No. of positive pigs/total no. of pigs 0/5 3/5 1/5 1/5
“-”, negative MCqPCR result; “o”, no parasite DNA detected; p-load, parasite load. Data are presented as the mean number of T. gondii parasite per 10 g of tissue.
throughout the host to other organs. IFNγ drives the reversion
of these tachyzoites into bradyzoites, which then form cysts to
hide from the immune system (38, 39). It seems that in the
control and vaccine 1 group, infection triggered IFNγ-producing
T cells, which resulted in tissue cysts. The subsequent absence
of T. gondii antigens might have prevented their development
into long-lived memory T cells and upon disappearance of the
short-lived T. gondii-specific IFNγ-producing T cells, tissue cysts
released their content, resulting in a second wave of tachyzoites
and the associated IFNγ response. Alternatively, the decline
in IFNγ-producing T cells in blood upon infection of control
and vaccine 1 group might hint at their migration to infected
tissues. The different kinetics of IFNγ production in the vaccine
2 group might be explained by the broader antigenic range
of vaccine 2, resulting in T. gondii-specific antibodies and T
cells which might have controlled the parasite at the initial site
of infection.
This difference in IFNγ response might explain the different
ability of the two vaccines to prevent the dissemination of the
parasite DNA from the intestinal tissues to the other organs upon
challenge infection.
Here, the parasite load in challenge infected animals was
assessed by MC-qPCR. Although this technique does not
provide information on the viability of the parasites, it does
allow to quantify T. gondii DNA and to assess vaccine
efficacy. In contrast to the control groups and vaccine 1
group, parasite DNA was not detected in brain tissue and
skeletal muscle tissue (4/5 animals were negative) in vaccine
2 group, implying that this vaccine candidate might have
the ability to control T. gondii dissemination to these tissues.
Hence, it might be interesting to investigate if the induced
immune response after the first immunization suffices for
this. In both vaccine groups, most animals were positive for
parasite DNA in heart tissue. Heart muscles are well-connected
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FIGURE 5 | Presence of T. gondii parasite in the examined tissues upon challenge infection in the different vaccine groups. The data are presented as the number of
T. gondii parasites/10 g tissue based on a formula resulting from a standard curve established with known concentrations of parasites ranging from 100 to 105 spiked
in 100 g of muscle or 50 g of brain tissue sample (28). The solid horizontal line indicates the mean ±SD. *P < 0.05.
to the oxygenated blood circulation which ultimately could
help T. gondii growth and survival (40). Alternatively, the
induced immune responses might have been inadequate to
prevent infection of cardiac cells with T. gondii for reasons
yet unknown. Surprisingly, in the QuilA adjuvanted control
group no parasite was detected in the m. L. dorsi. These
results might indicate that the activation of the immune
system by QuilA accelerated T. gondii-specific immune responses
upon challenge infection, which were able to prevent the
dissemination of the parasite in this tissue. These findings
warrant further research.
In conclusion, infection of pigs with T. gondii is an
interesting model to evaluate vaccine strategies. Here, vaccine
2 seems to be a better vaccine candidate as compared to
vaccine 1 to elicit T. gondii specific antibody and T cell
responses which prevent dissemination of the parasite to the
brain upon oral infection in pigs. However, further research
is needed to confirm that the reduction in parasite DNA
load is correlated with decreased parasite infectivity of tissues
and to optimize the efficacy, the dose as well as the route
of administration.
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